BridgeBio Pharma’s Nulibry Approved as First Treatment for Molybdenum Cofactor Deficiency Type A
XTalks
MARCH 3, 2021
BridgeBio is dedicated to developing therapies for genetic diseases with unmet needs. In the analysis involving 31 patients, 13 were treated with Nulibry and compared to 18 genotype-matched untreated patients from the history control group. The approval was granted to BridgeBio Pharma, Inc.
Let's personalize your content